a16z Podcast: The Economics of Expensive Medicines

In the podcast, Andrew Lo and Jorge Conde dive into the complexities surrounding the economic value of cures, particularly gene and cell therapies that promise significant health improvements but come with exorbitant price tags. They draw a parallel between the costs of these therapies to property mortgages, suggesting that if a patient essentially ‘finances’ a cure, there needs to be a sustainable way for insurance companies to cover these expenses. They emphasize that unlike chronic conditions managed through monthly payments, cures should be viewed as long-term investments in health, questioning how to fairly assess their value in an insurance framework.

The discussion transitions to the role of health insurance companies in managing the financial implications of expensive cures. Lo asserts that while insurance can potentially cover the costs of these medicines, the traditional premium-payout model poses a challenge. If a patient switches from one insurance plan to another shortly after receiving a costly cure, the plan that footed the bill could end up at a financial disadvantage. To alleviate this issue, Lo proposes a mechanism where payments for cures can be amortized, similar to how home mortgages work, thereby distributing financial responsibility among insurers, regardless of patient migration.

A focal point of the conversation revolves around how to determine the value of a cure when there are varying perspectives among patients, payers, and society as a whole. Lo mentions that in countries like the UK, organizations like NICE assess the cost-effectiveness of medicines, while in the US, the discussion is far more fragmented. The intricacies of factoring quality-adjusted life years (QALYs) and the avoided costs over a patient’s lifetime add layers of complication, leading to the need for a more standardized approach to pricing cures that considers all stakeholders.

Lo draws attention to the financial risks associated with drug discovery, particularly in the evolving landscape of medical innovation. Despite increasing knowledge in the field, he notes that heightened understanding can lead to more complexities and risks, as new discoveries may inadvertently render existing treatments less effective. They also touch upon the systemic risks shared across therapies, particularly in gene therapies, highlighting how prior successes can inform future endeavors while simultaneously introducing common uncertainties.

The podcast concludes with reflections on the behavioral patterns of healthcare markets, likening them more to biological systems than traditional economic models. Lo explains that market fluctuations can resemble biological responses to stimuli, revealing the importance of adapting to innovations and regulatory changes. Hence, the interplay of various stakeholders—patients, insurers, and pharmaceutical companies—creates a dynamic that necessitates collaborative innovation and policy adjustments to navigate the challenges posed by expensive therapies.